Overview Request Sample Pages Request Customization Download PDF
You are viewing: UK Veterinary Monoclonal Antibodies Market analysis

The UK Veterinary Monoclonal Antibodies Market was valued at $73.7 Million in 2025 and projected to reach to $129.58 Million by 2030, representing a compound annual growth rate of 11.9%. The UK veterinary monoclonal antibodies market is positioned for sustained expansion, supported by increasing consumer spending on premium pet healthcare and growing awareness of immunotherapy benefits.

UK Veterinary Monoclonal Antibodies Market (2025-2030) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

UK Veterinary Monoclonal Antibodies Market Trends and Insights

  • The UK market is driven by increasing adoption of advanced immunotherapies in companion animal care, rising prevalence of chronic diseases in pets, and growing investment in veterinary biotechnology.
  • The UK's strong regulatory framework and established veterinary healthcare infrastructure position it as a key market within Europe for innovative monoclonal antibody therapeutics. During the forecast period from 2025 to 2030, the UK is expected to maintain a compound annual growth rate of 11.9%, reflecting heightened demand for targeted immunological treatments across both companion and production animals.
  • The UK market benefits from high pet ownership rates, increased spending on premium veterinary services, and collaboration between UK research institutions and pharmaceutical manufacturers.
  • Strategic partnerships and clinical trials conducted in the UK are accelerating the commercialization of novel monoclonal antibody products tailored to veterinary applications..

Key Market Statistics

  • CAGR (2025-2030) 11.9% CAGR
  • Market Size, 2025 ~USD 73.7 Million
  • Forecast, 2030 ~USD 129.58 Million
  • Country UK

UK Veterinary Monoclonal Antibodies Market Overview

Market Valuation Growth :

The UK veterinary monoclonal antibodies market is valued at $73.7 million in 2025, with a projected CAGR of 11.9% through 2030, reaching $129.58 million by forecast end.

Companion Animal Focus :

UK pet owners are increasingly investing in advanced immunotherapies for companion animals, driving demand for monoclonal antibody treatments in the domestic veterinary sector.

Regulatory Advantage :

The UK's robust regulatory framework and post-Brexit veterinary biotechnology initiatives create a competitive advantage for innovation and faster market entry of new therapeutic solutions.

Chronic Disease Management :

Rising prevalence of chronic diseases in UK pets, combined with growing investment in veterinary biotechnology, is accelerating adoption of targeted monoclonal antibody therapies.

UK Veterinary Monoclonal Antibodies Market Dynamics

  • UK veterinary clinics are adopting advanced diagnostic and treatment protocols, with monoclonal antibodies becoming integral to managing oncology, immunological, and inflammatory conditions in companion animals.
  • Investment in veterinary research institutions and biotech partnerships is strengthening the UK's position as a hub for veterinary therapeutic innovation.
  • The market will benefit from regulatory harmonization efforts and collaborative initiatives between UK veterinary organizations and international bodies, facilitating faster adoption of breakthrough treatments and expanding treatment indications..

Related Ecosystem

Animal Health

Top Technologies
  • Polymerase Chain Reaction (PCR) Tests
  • Porcine
  • Immunodiagnostics
  • Lateral Flow Assays
  • Microarrays
Top Companies
  • Zoetis Inc.
  • Patterson Companies, Inc.
  • Virbac
  • Elanco Animal Health Incorporated
  • BOEHRINGER INGELHEIM GMBH

    Key Takeaways

    • The UK veterinary monoclonal antibodies market is valued at $73.7 million in 2025 and is forecast to reach $129.58 million by 2030, representing a 11.9% CAGR.
    • The UK market is driven by high pet ownership, premium veterinary spending, and strong regulatory support for innovative immunotherapies.
    • The UK's established research institutions and pharmaceutical partnerships accelerate clinical development and commercialization of monoclonal antibody products.
    • The UK market is expected to maintain steady growth through 2030 as demand for targeted immunological treatments in companion and production animals increases.

    Veterinary Monoclonal Antibodies Market Report Scope

    Report Metric Details
    Base Year 2025
    Fastest Growing Segment BEDINVETMAB (LIBRELA) (Product)
    Forecast Period 2025-2030
    Growth Rate CAGR of 12.4% from 2025 to 2030
    Largest Segment SUBCUTANEOUS ROUTE OF ADMINISTRATION (Route Of Administration)
    Market Size Base Year (Billions) ~USD 1.71 (2025)
    Revenue Forecast (Billions) ~USD 3.06 (2030)
    Segments Covered Animal Type, Product, Route Of Administration, Therapy Area, End User, Animal Type 2023-2030

    UK Veterinary Monoclonal Antibodies Market Report Segmentation

    6 segment dimensions are covered across the global market.

    By Animal Type

    • Canines
    • Felines
    • Other Animal Types
    • Other Animals

    By Product

    • Bedinvetmab (Librela)
    • Canine Parvovirus Monoclonal Antibody (Cpma)
    • Frunevetmab (Solensia)
    • Gilvetmab
    • Lokivetmab (Cytopoint)
    • Other Products

    By Route Of Administration

    • Intravenous (Iv) Route Of Administration
    • Intravenous Route Of Administration
    • Oral Route Of Administration
    • Subcutaneous (Sc) Route Of Administration
    • Subcutaneous Route Of Administration

    By Therapy Area

    • Dermatology
    • Infectious Diseases
    • Oncology
    • Other Therapy Areas
    • Pain Management

    By End User

    • Other End Users
    • Veterinary Clinics
    • Veterinary Hospitals/ Specialty Centers
    • Veterinary Hospitals/Specialty Clinics
    • Veterinary Research & Academic Institutes

    By Animal Type 2023-2030

    • Canines
    • Felines
    • Other Animals

    UK: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY END USER, 2023–2030

    Segment2023202420252026202820292030CAGR (%)
    OTHER END USERS5.976.456.987.568.889.6410.478.4
    VETERINARY CLINICS25.1628.3131.935.9645.7751.6858.4412.9
    VETERINARY HOSPITALS/SPECIALTY CLINICS29.3932.7736.5940.8751.0957.1664.0411.8
    VETERINARY RESEARCH & ACADEMIC INSTITUTES5.275.86.397.048.579.4610.4610.4
    TOTAL65.7873.3281.8591.43114.31127.93143.411.9

    Target Audience

    • Veterinary Pharmaceutical Companies : UK-based and international pharma firms need market intelligence to develop monoclonal antibody products, plan UK market entry, and allocate R&D resources effectively.
    • Veterinary Clinics & Animal Hospitals : UK veterinary practitioners require market data to understand treatment adoption trends, justify investment in immunotherapy capabilities, and enhance service offerings.
    • Biotech & Life Sciences Investors : Investment firms and venture capitalists need UK market forecasts and growth metrics to evaluate funding opportunities in veterinary biotechnology and immunotherapy sectors.
    • Regulatory & Policy Bodies : UK veterinary regulatory authorities and government agencies use market data to inform policy decisions, licensing frameworks, and veterinary healthcare standards.
    • Pet Insurance & Healthcare Providers : UK pet insurance companies and animal healthcare networks need market insights to assess treatment costs, coverage strategies, and emerging therapeutic trends in companion animal care.

    Reasons to Buy this Report

    • UK-Specific Market Sizing : Access precise valuation data for the UK market ($73.7M in 2025) with country-specific CAGR (11.9%) to accurately forecast revenue opportunities and market penetration strategies.
    • Regulatory & Compliance Insights : Understand UK-specific regulatory pathways, post-Brexit veterinary approval processes, and compliance requirements essential for product launches and market entry planning.
    • Competitive Landscape Analysis : Identify key UK veterinary biotech players, market share distribution, and competitive positioning to inform partnership, acquisition, and differentiation strategies.
    • Customer Segmentation Data : Gain detailed insights into UK veterinary clinics, animal hospitals, and pet owner demographics to tailor marketing campaigns and distribution strategies effectively.
    • Growth Driver Identification : Understand UK-specific factors driving market growth—chronic pet diseases, premium care adoption, and biotech investment—to capitalize on emerging opportunities and trends.

    Frequently asked questions

    What is the current size of the UK veterinary monoclonal antibodies market?

    The UK veterinary monoclonal antibodies market is valued at $73.7 million in 2025 and is projected to grow to $129.58 million by 2030.

    What is the growth rate of the UK veterinary monoclonal antibodies market?

    The UK market is expected to grow at a compound annual growth rate (CAGR) of 11.9% from 2025 to 2030.

    What factors are driving growth in the UK veterinary monoclonal antibodies market?

    Key drivers include high pet ownership rates, increased spending on premium veterinary services, rising prevalence of chronic diseases in animals, and strong regulatory support for innovative immunotherapies in the UK.

    Which animal segments are most significant in the UK market?

    The UK market serves both companion animals (dogs, cats) and production animals, with companion animal care representing a substantial portion due to high pet ownership and premium spending patterns in the UK.

    How does the UK market compare to other European markets?

    The UK's established veterinary healthcare infrastructure, strong regulatory framework, and active research institutions position it as a leading market within Europe for veterinary monoclonal antibody therapeutics.

    RESEARCH METHODOLOGY

    This study involved the extensive use of both primary and secondary sources. The research process involved evaluating various factors affecting the industry to identify the segmentation, industry trends, key players, competitive landscape, market dynamics, and growth strategies.

    Secondary Research

    In the secondary research process, various secondary sources were referred to, including directories, databases such as Bloomberg Business, Factiva, and Dun & Bradstreet; white papers, annual reports, company house documents, investor presentations, and SEC filings of companies. Secondary research was used to identify and collect valuable information for an extensive, technical, market-oriented, and commercial study of the veterinary monoclonal antibodies market. It was also used to obtain information about the key players, market classification & segmentation according to industry trends to the bottommost level, and key developments related to market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.

    Primary Research

    In the primary research process, various primary sources from the supply and demand sides were interviewed to obtain critical qualitative and quantitative information for this report. Primary sources from the supply side include project/sales/marketing/business development managers, presidents, vice presidents, chairpersons, chief executive officers, chief operating officers, chief strategy officers, directors, chief information officers, and chief medical information officers related to the veterinary monoclonal antibodies market. Primary sources from the demand side include professionals from veterinary hospitals and clinics, academic & research institutes, and pet owners.

    Breakdown of primary interviews

    Veterinary Monoclonal Antibodies Market

    Note: Companies are classified into tiers based on their total revenue. As of 2024, Tier 1 = >USD 10.00 billion, Tier 2 = USD 1.00 billion to USD 10.00 billion, and Tier 3 = < USD 1.00 billion.

    Other designations include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.

    To know about the assumptions considered for the study, download the pdf brochure

    Market Size Estimation

    The total size of the veterinary monoclonal antibodies market was determined after data triangulation from two approaches, as mentioned below. After each approach, the weighted average of these approaches was taken based on the level of assumptions used in each approach.

    Veterinary Monoclonal Antibodies Market

    Data Triangulation

    After arriving at the market size, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were employed wherever applicable to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments.

    Market Definition

    Veterinary monoclonal antibodies are laboratory-produced antibodies designed to target specific antigens in animals, offering precise treatment for conditions like atopic dermatitis, osteoarthritis, and infectious diseases. These species-specific biologics are engineered to work effectively in the immune systems of dogs, cats, or livestock. They represent a significant advancement over traditional drugs by providing targeted therapy with fewer side effects.

    Stakeholders

    • Veterinary monoclonal antibody manufacturers
    • Animal healthcare product manufacturers
    • Veterinary monoclonal antibody distributors and wholesalers
    • Animal welfare associations
    • Veterinary clinics and care centers
    • Research and consulting firms
    • Veterinary R&D organizations
    • Contract research organizations
    • Contract manufacturing organizations
    • Venture capitalists

    Report Objectives

    • To define, describe, and forecast the veterinary monoclonal antibodies market by animal type, product, therapy area, route of administration, end user, and region
    • To identify and analyze key drivers, restraints, opportunities, and challenges influencing market growth
    • To strategically analyze the regulatory scenario, value chain analysis, supply chain analysis, Porter’s Five Forces analysis, ecosystem analysis, trade analysis, pricing analysis, patent analysis, impact of AI, case study analysis, adjacent market analysis, unmet needs/end user expectations, and trends and disruptions impacting customer business in the market
    • To analyze micro markets with respect to individual growth trends, prospects, and contributions to the overall market
    • To analyze opportunities for stakeholders and provide details of the competitive landscape for key players
    • To strategically profile key players in this market and comprehensively analyze their market shares and core competencies
    • To track and analyze competitive developments such as product launches and approvals, partnerships, and expansions in the market

    Get the Full Veterinary Monoclonal Antibodies Market Report

    Full forecast, segment splits, and company analysis for all Veterinary Monoclonal Antibodies Market.

    Download Sample Pages Buy Report

    METHODOLOGY

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    Cite this Research
    DMCA.com Protection Status